Revolution Medicines reports FY2022 net loss $248.7M; cash $644.9M; provides clinical updates

Revolution Medicines, Inc.

2022-FY EPS reported -$3.08 revenue$35,380,000

Net loss $248.7M for FY2022 vs $187.1M in 2021; Q4 net loss $56.5M.
Cash, equivalents and securities $644.9M as of Dec 31, 2022; expects to fund operations through 2024.
Revenue $35.4M in FY2022 includes $7.6M non-cash adjustment from Sanofi collaboration termination.
RMC-6236 shows early antitumor activity: 12 evaluable patients all stable or better, 10 with tumor reductions, 2 partial responses.
Sanofi terminates SHP2 collaboration effective June 2023; Revolution regains global rights to RMC-4630.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Revolution Medicines, Inc. reported financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 27, 2023, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Revolution Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-004638

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.